MoonLake Immunotherapeutics (MLTX)
12.58
+0.28
(+2.23%)
USD |
NASDAQ |
Oct 29, 16:00
12.32
-0.26
(-2.11%)
After-Hours: 20:00
MoonLake Immunotherapeutics Enterprise Value : 593.70M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | 593.70M |
| October 27, 2026 | 561.93M |
| October 26, 2026 | 551.90M |
| October 23, 2026 | 555.24M |
| October 22, 2026 | 596.21M |
| October 21, 2026 | 454.91M |
| October 20, 2026 | 427.32M |
| October 19, 2026 | 379.67M |
| October 16, 2026 | 362.95M |
| October 15, 2026 | 422.31M |
| October 14, 2026 | 412.27M |
| October 13, 2026 | 434.85M |
| October 12, 2026 | 457.42M |
| October 09, 2026 | 469.13M |
| October 08, 2026 | 449.06M |
| October 07, 2026 | 464.95M |
| October 06, 2026 | 480.00M |
| October 05, 2026 | 515.95M |
| October 02, 2026 | 518.45M |
| October 01, 2026 | 523.47M |
| September 30, 2026 | 542.70M |
| September 29, 2026 | 521.80M |
| September 28, 2026 | 531.00M |
| September 25, 2026 | 571.13M |
| September 24, 2026 | 577.82M |
| Date | Value |
|---|---|
| September 23, 2026 | 643.03M |
| September 22, 2026 | 683.16M |
| September 21, 2026 | 613.77M |
| September 18, 2026 | 600.39M |
| September 17, 2026 | 597.04M |
| September 16, 2026 | 606.24M |
| September 15, 2026 | 584.50M |
| September 14, 2026 | 624.64M |
| September 11, 2026 | 610.42M |
| September 10, 2026 | 666.44M |
| September 09, 2026 | 711.59M |
| September 08, 2026 | 813.59M |
| September 04, 2026 | 819.44M |
| September 03, 2026 | 834.49M |
| September 02, 2026 | 823.62M |
| September 01, 2026 | 829.47M |
| August 31, 2026 | 822.78M |
| August 28, 2026 | 817.77M |
| August 27, 2026 | 862.91M |
| August 26, 2026 | 870.44M |
| August 25, 2026 | 865.42M |
| August 24, 2026 | 849.54M |
| August 21, 2026 | 882.14M |
| August 20, 2026 | 891.34M |
| August 19, 2026 | 964.08M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| BeOne Medicines Ltd. | 35.68B |
| AC Immune SA | 127.57M |
| CRISPR Therapeutics AG | 3.649B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.80M |
| Total Expenses (Quarterly) | 61.80M |
| EPS Diluted (Quarterly) | -0.8362 |
| Earnings Yield | -30.48% |
| Normalized Earnings Yield | -30.48 |